Extremely low-intensity electromagnetic fields for therapeutic use
Since its inception in 2000, the Humanism and Science Foundation has led a series of pioneering research projects in collaboration with renowned academic and medical institutions both nationally and internationally. These efforts have culminated in the development and clinical validation of Zentria Technology, an innovative therapeutic approach based on low-intensity electromagnetic fields. With studies covering conditions ranging from fibromyalgia to sleep disorders and stress, the Foundation has consistently demonstrated the effectiveness of Zentria Technology in improving patients' quality of life.
The Humanism and Science Foundation, a nonprofit scientific research entity, began developing research projects in 2000 through collaboration agreements with research teams affiliated with universities and scientific research centers: the University of Alcalá de Henares, the Complutense and Polytechnic Universities of Madrid, the Ruber International Hospital in Madrid, and the University of Zaragoza (Research Department of the Faculty of Medicine and the European Foundation for Bioelectromagnetism). These research teams were dedicated to studying the effects of externally induced, extremely low-intensity electrical impulses on human cellular structures, specifically focusing on brain activity
In order to better understand and analyze in detail the cellular-level changes induced by our technology and the underlying mechanisms of action, it became necessary to expand the project into other areas that would allow for technique validation and knowledge expansion. To this end, a Research Collaboration Agreement was signed between the Humanism and Science Foundation and Dr. María Jesús Azanza, Professor of Biology and Magnetobiology at the Faculty of Medicine of the University of Zaragoza, along with Dr. Ceferino Maestú Unturbe, to conduct various projects within the Department of Anatomy and Human Histology. The results of their studies were presented in several publications and at the conferences in Budapest (2003), Thessaloniki (2004), and Dublin (2005) (14, 15)
The Congress of the Spanish Society of Neuroscience, held in 2005, recognized that our technology was capable of synchronizing the synaptic frequency of two adjacent neurons, modulating their activity to normal parameters. These bioelectrical effects, based on the referenced scientific studies, were further developed by the Humanism and Science Foundation and form the background and current foundation of what is now known as Zentria Technology. (1,2,3,4)(16)
The 'Humanism and Science Foundation,' based on studies conducted not only in Spain but also in Europe and the U.S., completed the development of a double-blind, randomized clinical study in 2006 at the facilities of the 'USP Sagrado Corazón de Jesús' Clinic in Seville, now Hospital Quirón, on fibromyalgia.
The trial was conducted using a programmable GMB Magnetic Stimulator (low-intensity transcranial stimulator) with patent application number 200501477, filed on June 17, 2005, and a Transcranial Magnetic Stimulation Helmet that allows for the simultaneous recording of EEG activity, protected by patent 200302955, filed on December 16, 2003
The results of the trial enabled the authorization for the manufacturing and sale of the Magnetic Stimulator as a Medical Device by the Spanish Agency of Medicines (AEMPS) and led to the registration of patents 200601523, 200602145, and 200700081. (5,6,7)
From 2006 to 2010, the Humanism and Science Foundation, as the entity through which BZ I&D Laboratories carries out its research activities, continued conducting studies and investigations at the University of Zaragoza, in collaboration with Dr. María Jesús Azanza Ruiz and her team, composed of Dr. Álvaro del Moral Calvo and Dr. Rodolfo Pérez Bruzón (8,9).
To verify the safety of this technology, various studies were conducted in the laboratory to assess potential adverse effects induced by the Zentria Technology for its use in clinical applications.
Starting in 2009, following the confirmation of the efficacy of Zentria Technology in normalizing cellular activity as demonstrated in previous years' studies, and based on clinical observations of improvements in stress and sleep disorders, new clinical studies on depression and stress began to be developed using the RBF regulator.
During the first half of 2011, a new study was conducted to assess the effects of Zentria Technology on stress-related disorders. This study, sponsored by the Humanism and Science Foundation, once again provided clinical evidence of the efficacy of Zentria Technology in improving stress-related symptoms in the majority of the subjects studied. In collaboration with Dr. Manuel Rodrigo in Puertollano (Ciudad Real), results were evaluated using objective measures through psychometric scales (STAI and KAV-103) administered before and after the therapy. The treatment results showed measurable improvement ranging from 78.6% to 85.71%, depending on the parameter studied (state anxiety / generalized anxiety disorder), with a parallel improvement in depressive symptoms observed in 71.42% of the patients. (11)
In line with the philosophy and principles of the Humanism and Science Foundation, aimed at putting technological advances at the service of society, several studies were conducted during the last quarter of 2011 at the Foundation’s own facilities to assess the specific effectiveness of Zentria Technology on sleep disorders. Specific parameters were measured, such as difficulties falling asleep, interruptions during sleep, dream activity, subjective perception of nighttime rest, and morning alertness. The results were compiled in an internal report by the Humanism and Science Foundation, showing overall improvement rates exceeding 80% in the symptoms previously reported. This study was led and conducted by the Foundation’s Medical Director, Dr. Ignacio Marzo. (12)
In July 2014, the Humanism and Science Foundation took a further step in its commitment to making Zentria Technology more accessible. Through BZ I&D Laboratories, S.L., it developed new models of biophysiological regulators designed for individual use at home. To verify the efficacy of these regulators, several studies were conducted between September 2014 and January 2015, aimed at confirming the correlation between the normalization and regeneration of cellular energy and the reduction or disappearance of symptoms associated with stress-related disorders. (13).
The results of these studies were documented in the corresponding internal reports of the Humanism and Science Foundation and confirmed the efficacy of the technology, regardless of the type of applicator or biophysiological regulator used.
Throughout 2016, various collaborations and studies were launched based on research conducted outside the laboratory setting. The focus was on real-world results obtained from individuals without prior pathologies, following the direct application of Zentria Technology.
These investigations assess and evaluate the effect of our technology on healthy individuals randomly selected from the general population. The refinement of our technology is the driving force behind these types of studies, aimed at providing users with the most advanced and effective system to enhance their well-being and quality of life (14)
Currently, two new studies have been initiated to evaluate the efficacy of different types of biophysiological regulators in addressing sleep disorders, relaxation, and vitality.
All previous studies and results have led to the development of an improved and continuously evolving Zentria Technology, which is commercialized by BZ I&D Laboratories, S.L. The application of Zentria Technology has materialized in several devices intended for both clinical and personal use.
(1).- Thessaloniki Congress September 2004. “The human brain influenced by picoteslas magnetic stimulation: evidence from EEG & fMRI simultaneous Recordings” (September 2004) and “Method for simultaneous electromagnetic stimulation and electrical recording of the human brain” (2004), presented by the team from the University of Alcalá de Henares, led by Dr. J. L. Bardasano and integrated by, among others, Drs. C. Maestu Unturbe and J. M. Rodríguez Delgado and sponsored by the Humanism and Science Foundation.
(2).- “ELF magnetic fields induced effects on the bioelectric activity of single neuron cells: Helix Aspersa single unit neuron show a frequency window phenomena under applied magnetic fields of variable frequency” (2002), “Evidence of synchronicity of neuron activity of molluscan brain ganglia induced by alternating 50 Hz applied magnetic field” (2002), and “Reversibility of effects induced on the spontaneous bioelectric activity of neuron under exposure to low intensity magnetic fields” (2002), presented by the team from the University of Zaragoza, led by Dr. M. J. Azanza and integrated, among others, by doctors A. Del Moral, Calvo and Pérez Bruzón and sponsored by the Humanism and Science Foundation.
(3).- Approval by the Spanish Agency of Medicines and Health Products (AEMPS) for the use of our GMB-03 equipment as a treatment for Fibromyalgia. Project to test the efficacy and safety of low-intensity magnetic stimulation on fibromyalgia disease 2006. Principal investigators: Dr. M. Blanco Suárez and Dr. C. Maestu Unturbe; trial monitor: Dr. P. Fernández-Argüelles Vinteno; Clinical Research Ethics Committee, “Virgen Macarena” University Hospital; other members of the study: Dr. J. Bautista Lorite, Dr. J. Romero Aleta, Dr. J. Galindo Ocaña, Dr. P. Rodríguez-Rubio Cortadellas, and Dr. F. De Ia Morena.
(4).- “EMBC-FD-001 Protocol, “Proof of concept” study of the efficacy and safety of low-intensity magnetic stimulation on fibromyalgia disease”.
(5).- With patent application number 200501477, dated June 17, 2005.
(6).- Protected by patent 200302955 of December 16, 2003.
(7).- With the registration of patents 200601523, 200602145 and 200700081.
(8).- “Study of the dependence of the response of isolated Helix aspersa neurons on the frequency of magnetic fields” Final degree project by Dr. Ana Moreno del Río. Polytechnic University of Madrid (2006).
(9).- Dr. M. J. Azanza, “Dynamics of neural networks and electromagnetic fields: assessment of the possible adverse effects induced by a low frequency and intensity magnetic field used for clinical purposes” (2005-2011) and “Dynamics of neural networks and electromagnetic fields: effects induced by a low frequency and intensity magnetic field on neuronal electrophysiological activity” (2005-2010).
(11).- “Study on the effectiveness of Zentria Technology in correcting symptoms derived from stress disorders” (2011), carried out by the Humanism and Science Foundation, directed by Dr. I.J. Marzo and collaborator, S. Arias.
(12).- “Study of the effectiveness of Zentria Technology on different sleep parameters” (2011), carried out by the Humanism and Science Foundation, directed by Dr. I.J. Marzo.
(13).- “Comparative study of the effectiveness of Zentria Technology applied with different biophysiological regulators on anxiety disorders” (2014-2015), carried out by the Humanism and Science Foundation, directed by Dr. I.J. Marzo.
(14).- “Study of the effectiveness of Zentria Technology on anxiety and stress disorders through psychometric evaluation and recording of physiological constants” (2015), carried out by the Humanism and Science Foundation, directed by psychologist D. J. Briceño as head of the psychological area, and by Dr. I.J. Marzo as head of the medical area.
(15) Dublin Congress. “Elemental neuron network dynamics under applied magnetic fields” and “Characterization of Connexius in neurons submitted to applied EMF” 2005.
(16) 6th International Congress of the European Bioelectromagnetism Association EBA 2003 Budapest, Hungary, November 13-15, 2003.
(17) Congress of the Spanish Society of Neuroscience of Torremolinos 2005. Presentation “Modification of neuronal dynamics under exposure to extremely low frequency magnetic fields”.
